ClinicalTrials.gg
CompletedNCT04159805Updated Jun 2, 2023Results posted

A Study of TAK-079 in People With Generalized Myasthenia Gravis

A Phase 2 interventional study of TAK-079 and TAK-079 Placebo in Myasthenia Gravis, sponsored by Takeda. Completed at 50 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-02.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Enrollment
65th of 108
36 · median 56
Started
2020
with 3 others
Phase 2
26 of 144
5 open now
Registered
51st of 144
by date

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 65th largest by enrollment of the 108 interventional ones that give a count, is one of 4 that started in 2020, is one of 26 in phase 2, and was the 51st registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means the body makes antibodies that attack its own cells and tissues. These types of antibodies are also known as autoantibodies. People with generalized myasthenia gravis have a weakness in many muscles.

TAK-079 is a medicine to help people with generalized myasthenia gravis.

The main aim of this study is to check if people with generalized myasthenia gravis have side effects from 2 doses of TAK-079. Other aims are to learn if TAK-079 improves their clinical condition and lowers their autoantibody levels.

At the first visit, the study doctor will check if each person can take part. For those who can take part, participants will continue with their standard medicines for this condition during the study. Each participant will have a check-up by the study doctor.

Then, the participants will have 1 of 3 treatments:

  • A low dose of TAK-079.
  • A high dose of TAK-079.
  • A placebo. In this study, a placebo looks like TAK-079 but does not have any medicine in it.

Participants will not know which treatment they received, nor will their study doctors. This is to help make sure the results are more reliable.

For each treatment, participants will receive injections just under the skin, once a week for 8 weeks. The study doctors will check for side effects from the study treatments. The study doctors can stop or delay the injections in each participant if needed.

Then, the study doctors will continue to check for side effects for up to 24 weeks after treatment. They will also check the clinical condition of the participants, including their autoantibody levels.

Read the detailed description

Myasthenia gravis (MG) is an autoimmune disorder in which autoantibodies, such as those targeting the nicotinic acetylcholine receptor (AChR) or muscle specific kinase (MuSK), interfere with neuromuscular transmission, resulting in fatigue and weakness.

The drug being tested in this study is called TAK-079. TAK-079 is being tested to treat people who have generalized myasthenia gravis.

03

Conditions studied

  • Myasthenia Gravis

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Diagnosis of Myasthenia Gravis (MG) supported by a positive serologic test for anti-AChR or anti-MuSK antibodies at screening.
  2. Myasthenia Gravis Foundation of America (MGFA) clinical classification II to IV at screening.
  3. Myasthenia Gravis Activities of Daily Living (MG-ADL) total score of 6 or greater at screening, with at least 4 points attributed to nonocular items.
  4. If receiving drugs (ie, mycophenolate mofetil, methotrexate, cyclosporine, tacrolimus, cyclophosphamide), therapy must be ongoing for at least 6 months, with stable dosing ongoing for at least 3 months before screening. Participants receiving azathioprine must be on a stable dose for at least 6 months before screening.
  5. If receiving oral , therapy must be ongoing for at least 3 months, with a stable dose at least 1 month before screening. Corticosteroids, including dexamethasone, must be given as oral, daily or every-other-day therapy, as opposed to pulse therapy.
  6. If receiving cholinesterase inhibitors, therapy with a stable dose is required at least 2 weeks before screening.
  7. The doses of concomitant standard background therapy must be expected to remain stable throughout the study unless dose reduction is required due to toxicities. Allowed background therapy is defined as no more than a cholinesterase inhibitor ± corticosteroid ± 1 steroid-sparing immunosuppressive drug (limited to azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, tacrolimus, or cyclophosphamide). Participants must be on at least one allowed background medication.

Main Exclusion Criteria:

  1. Presence of a thymoma (previous history of a fully encapsulated thymoma removed ≥ 12 months before screening is allowed) or history of invasive thymic unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening.
  2. History of thymectomy within 12 months before screening.
  3. MGFA class I or V.
  4. Received intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), or plasmapheresis/plasma exchange within 4 weeks before screening, or an expectation that any therapy besides the participants standard background therapies may be used for treatment of MG (eg, a rescue therapy) between screening and dosing.
  5. (COPD) or asthma with a pre-bronchodilatory (FEV1) \<50% of predicted normal.

    Note: FEV1 testing is required for participants suspected of having COPD or asthma.

  6. Received rituximab, belimumab, eculizumab, or any monoclonal antibody for immunomodulation within 6 months before first dosing. Participants with prior exposure to rituximab must have CD19 counts within the normal range at screening.
  7. Known disease other than MG that could interfere with the course and conduct of the study.
  8. Received a within 4 weeks before screening or has any live vaccination planned during the study.
  9. Opportunistic infection ≤12 weeks before initial study dosing or currently receiving treatment for a chronic opportunistic infection, such as tuberculosis (TB), pneumocystis pneumonia, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria. A mild, localized herpes simplex infection within 12 weeks of study dosing is allowed, as long as the lesion has resolved without systemic therapy prior to Day 1.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Placebo comparator
    TAK-079 Placebo-matching

    TAK-079 placebo-matching injection, subcutaneously (SC), once weekly in combination with standard background therapy for 8 weeks.

    Drug: TAK-079 Placebo

  • Experimental
    TAK-079 300 mg

    TAK-079 300 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.

    Drug: TAK-079

  • Experimental
    TAK-079 600 mg

    TAK-079 600 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.

    Drug: TAK-079

Interventions

  • TAK-079 subcutaneous injection

    Also known as: Mezagitamab

  • DrugTAK-079 Placebo

    TAK-079 placebo-matching subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 or Higher TEAEs, and Adverse Event (AE) Leading to TAK-079 Discontinuation

    AE is defined as any untoward medical occurrence in clinical investigation participant administered drug; it does not necessarily have to have causal relationship with this treatment. TEAE is defined as AE with onset that occurs after receiving study drug. SAE is an adverse event resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Severity of TEAEs was graded using National cancer institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 definitions of Grade 1 through Grade 5 wherein Grade 1=mild symptoms, Grade 2=moderate symptoms, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening consequences and Grade 5=death related to AEs. Percentages are rounded off to whole number at single decimal.

    Time frame: From signing the informed consent form up to end of long-term follow-up (up to Week 32)

Secondary outcomes

  1. Change From Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score

    Participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. Negative change indicates improvement. Mixed-effects model for repeated measures (MMRM) was used for the analysis.

    Time frame: Baseline up to Week 32

  2. Change From Baseline in Quantitative Myasthenia Gravis (QMG) Scale Score

    Physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. Negative change indicates improvement. MMRM was used for the analysis.

    Time frame: Baseline up to Week 32

  3. Change From Baseline in Myasthenia Gravis Composite (MGC) Scale Score

    An assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Items are scored based on 4 potential levels of impact: normal, mild, moderate, or severe with a total score of 0 to 50; the higher score indicates worse MG disease activity. Negative change indicates improvement. MMRM was used for the analysis.

    Time frame: Baseline up to Week 32

  4. Change From Baseline in Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) Scale Score

    A participant-reported score that assesses the participant's perception of impairment and disability and the degree to which the participant tolerates disease manifestations. Each question is graded on a 3-point scale from 0=normal to 2=severe with a total score of 0 to 30; the higher score indicates worse MG disease activity. Negative change indicates improvement. MMRM was used for the analysis.

    Time frame: Baseline up to Week 32

  5. Change From Baseline in Anti-acetylcholine Receptor (AChR) Antibody Levels

    Clinical laboratory evaluations of anti-AChR antibodies were tested to monitor disease activity. MMRM was used for the analysis.

    Time frame: Baseline up to Week 32

  6. Change From Baseline in Anti- Muscle-specific Tyrosine Kinase (MuSK) Titer Levels

    Clinical laboratory evaluations of anti-MuSK antibodies were tested to monitor disease activity. Data is reported for participants who were positive for anti-MuSK antibodies at baseline.

    Time frame: Baseline up to Week 32

  7. Percentage of Participants With 2-point Reduction in MG-ADL Total Score

    The percentage of responders with at least a 2-point reduction in MG-ADL total score from baseline is reported. MG-ADL is a participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. Percentages are rounded off to whole number at the nearest decimal.

    Time frame: At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32

  8. Percentage of Participants With 3-point Reduction in QMG Total Score

    The percentage of responders with at least a 3-point reduction in QMG total score from baseline is reported. QMG is a physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. Percentages are rounded off to whole number at the nearest decimal.

    Time frame: At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32

  9. Percentage of Participants With 3-point Reduction in MGC Total Score

    The percentage of responders with at least a 3-point reduction in MGC total score from baseline is reported. MGC is an assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Items are scored based on 4 potential levels of impact: normal, mild, moderate, or severe with a total score of 0 to 50; the higher score indicates worse MG disease activity. Percentages are rounded off to whole number at the nearest decimal.

    Time frame: At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32

07

Results

Posted Jun 2, 2023

Participant flow

Participants took part in the study at 15 investigative sites in the United States, Spain, Poland, Serbia, and Canada from 14 January 2020 to 12 July 2022.

Participant flow — Overall Study
MilestoneTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
Started121212
Completed121010
Not completed022
Withdrew: Withdrawal by subject022

Outcome measures

PrimaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 or Higher TEAEs, and Adverse Event (AE) Leading to TAK-079 Discontinuation

AE is defined as any untoward medical occurrence in clinical investigation participant administered drug; it does not necessarily have to have causal relationship with this treatment. TEAE is defined as AE with onset that occurs after receiving study drug. SAE is an adverse event resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Severity of TEAEs was graded using National cancer institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 definitions of Grade 1 through Grade 5 wherein Grade 1=mild symptoms, Grade 2=moderate symptoms, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening consequences and Grade 5=death related to AEs. Percentages are rounded off to whole number at single decimal.

Time frame:
From signing the informed consent form up to end of long-term follow-up (up to Week 32)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 or Higher TEAEs, and Adverse Event (AE) Leading to TAK-079 Discontinuation
percentage of participantsTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
TEAE66.775.091.7
SAE8.38.38.3
Grade 3 or Higher TEAEs16.78.38.3
AE Leading to TAK-079 Discontinuation0.00.00.0
SecondaryChange From Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score

Participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. Negative change indicates improvement. Mixed-effects model for repeated measures (MMRM) was used for the analysis.

Time frame:
Baseline up to Week 32
Reported as:
Mean · score on a scale
Change From Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score
score on a scaleTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
Change From Baseline at Week 4-2.8 ± 2.67-2.5 ± 2.47-1.8 ± 1.66
Change From Baseline at Week 6-4.0 ± 2.73-4.2 ± 2.64-2.3 ± 2.15
Change From Baseline at Week 8-3.8 ± 2.80-4.3 ± 3.10-2.0 ± 3.16
Change From Baseline at Week 10-4.0 ± 3.52-5.0 ± 2.41-2.0 ± 2.79
Change From Baseline at Week 12-4.2 ± 3.19-4.2 ± 2.56-2.5 ± 2.68
Change From Baseline at Week 14-4.0 ± 4.38-4.8 ± 2.20-2.0 ± 3.30
Change From Baseline at Week 16-4.1 ± 3.21-4.3 ± 2.79-3.1 ± 3.48
Change From Baseline at Week 20—-3.9 ± 3.60-2.9 ± 3.11
Change From Baseline at Week 24—-4.1 ± 3.62-3.0 ± 3.57
Change From Baseline at Week 28—-3.9 ± 3.96-3.1 ± 3.37
Change From Baseline at Week 32—-2.3 ± 4.61-2.8 ± 3.99
Statistical analysis
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.772 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in least square (ls) mean: 0.29 · 95% CI -1.72 to 2.30
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.299 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 1.01 · 95% CI -0.94 to 2.97
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.924 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.11 · 95% CI -2.34 to 2.13
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.091 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 1.86 · 95% CI -0.32 to 4.04
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.887 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.18 · 95% CI -2.82 to 2.45
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.162 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 1.80 · 95% CI -0.76 to 4.36
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.784 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.36 · 95% CI -3.01 to 2.29
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.166 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 1.79 · 95% CI -0.79 to 4.37
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.724 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.42 · 95% CI -1.98 to 2.82
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.124 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 1.81 · 95% CI -0.52 to 4.14
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.856 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.29 · 95% CI -2.91 to 3.48
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.292 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 1.64 · 95% CI -1.48 to 4.76
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.944 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.11 · 95% CI -3.14 to 3.37
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.589 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.85 · 95% CI -2.33 to 4.02
SecondaryChange From Baseline in Quantitative Myasthenia Gravis (QMG) Scale Score

Physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. Negative change indicates improvement. MMRM was used for the analysis.

Time frame:
Baseline up to Week 32
Reported as:
Mean · score on a scale
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Scale Score
score on a scaleTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
Change From Baseline at Week 4-1.0 ± 2.34-2.0 ± 2.70-0.2 ± 2.89
Change From Baseline at Week 6-0.9 ± 1.76-2.5 ± 3.24-1.3 ± 3.10
Change From Baseline at Week 8-1.0 ± 2.30-3.4 ± 3.35-0.9 ± 3.27
Change From Baseline at Week 10-1.4 ± 2.87-3.2 ± 3.09-0.7 ± 4.03
Change From Baseline at Week 12-2.8 ± 2.68-3.9 ± 2.55-0.8 ± 3.51
Change From Baseline at Week 14-1.9 ± 3.11-3.5 ± 2.510.6 ± 4.65
Change From Baseline at Week 16-1.2 ± 3.22-3.3 ± 3.43-0.3 ± 4.81
Change From Baseline at Week 20—-1.9 ± 3.56-0.5 ± 4.27
Change From Baseline at Week 24—-2.2 ± 4.47-0.6 ± 3.78
Change From Baseline at Week 28—-1.7 ± 3.80-0.8 ± 4.52
Change From Baseline at Week 32—-0.7 ± 4.27-0.1 ± 4.79
Statistical analysis
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.406 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.93 · 95% CI -3.17 to 1.31
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.418 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.90 · 95% CI -1.34 to 3.14
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.463 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.94 · 95% CI -3.53 to 1.65
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.936 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.10 · 95% CI -2.70 to 2.49
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.170 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -1.80 · 95% CI -4.41 to 0.82
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.687 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.52 · 95% CI -2.10 to 3.13
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.374 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -1.24 · 95% CI -4.05 to 1.57
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.478 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.99 · 95% CI -1.82 to 3.80
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.690 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.51 · 95% CI -3.12 to 2.09
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.106 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 2.12 · 95% CI -0.48 to 4.71
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.547 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.89 · 95% CI -3.89 to 2.12
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.144 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 2.19 · 95% CI -0.81 to 5.18
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.431 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -1.37 · 95% CI -4.91 to 2.17
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.488 · Difference in ls mean: 1.20 · 95% CI -2.34 to 4.74
SecondaryChange From Baseline in Myasthenia Gravis Composite (MGC) Scale Score

An assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Items are scored based on 4 potential levels of impact: normal, mild, moderate, or severe with a total score of 0 to 50; the higher score indicates worse MG disease activity. Negative change indicates improvement. MMRM was used for the analysis.

Time frame:
Baseline up to Week 32
Reported as:
Mean · score on a scale
Change From Baseline in Myasthenia Gravis Composite (MGC) Scale Score
score on a scaleTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
Change From Baseline at Week 4-4.2 ± 3.69-4.9 ± 3.82-1.1 ± 5.92
Change From Baseline at Week 6-7.3 ± 4.29-6.1 ± 5.24-4.9 ± 4.74
Change From Baseline at Week 8-5.5 ± 4.03-7.4 ± 4.63-2.4 ± 6.10
Change From Baseline at Week 10-7.8 ± 5.86-7.6 ± 5.07-2.6 ± 6.55
Change From Baseline at Week 12-7.3 ± 5.00-8.5 ± 3.11-5.1 ± 5.11
Change From Baseline at Week 14-6.1 ± 6.52-9.7 ± 3.83-0.9 ± 8.25
Change From Baseline at Week 16-6.6 ± 4.95-9.2 ± 5.18-2.9 ± 6.45
Change From Baseline at Week 20—-7.3 ± 5.20-2.6 ± 7.21
Change From Baseline at Week 24—-7.1 ± 5.78-3.3 ± 7.30
Change From Baseline at Week 28—-5.6 ± 6.40-4.1 ± 7.59
Change From Baseline at Week 32—-3.4 ± 8.13-2.5 ± 8.07
Statistical analysis
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.855 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.34 · 95% CI -4.14 to 3.45
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.093 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 3.19 · 95% CI -0.56 to 6.95
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.410 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 1.80 · 95% CI -2.61 to 6.20
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.154 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 3.13 · 95% CI -1.25 to 7.50
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.662 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.94 · 95% CI -5.29 to 3.41
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.130 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 3.26 · 95% CI -1.02 to 7.54
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.586 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 1.27 · 95% CI -3.44 to 5.98
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.039 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 4.93 · 95% CI 0.26 to 9.60
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.909 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.22 · 95% CI -4.03 to 3.60
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.158 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 2.65 · 95% CI -1.09 to 6.40
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.764 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.88 · 95% CI -6.80 to 5.05
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.080 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 5.20 · 95% CI -0.67 to 11.06
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.677 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -1.01 · 95% CI -5.98 to 3.95
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.055 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 4.81 · 95% CI -0.10 to 9.73
SecondaryChange From Baseline in Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) Scale Score

A participant-reported score that assesses the participant's perception of impairment and disability and the degree to which the participant tolerates disease manifestations. Each question is graded on a 3-point scale from 0=normal to 2=severe with a total score of 0 to 30; the higher score indicates worse MG disease activity. Negative change indicates improvement. MMRM was used for the analysis.

Time frame:
Baseline up to Week 32
Reported as:
Mean · score on a scale
Change From Baseline in Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) Scale Score
score on a scaleTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
Change From Baseline at Week 4-3.1 ± 3.85-3.9 ± 4.46-3.2 ± 4.43
Change From Baseline at Week 6-4.3 ± 4.11-5.8 ± 6.00-3.4 ± 3.53
Change From Baseline at Week 8-3.2 ± 4.00-5.6 ± 6.53-3.3 ± 3.74
Change From Baseline at Week 10-2.5 ± 6.12-6.3 ± 6.07-3.9 ± 3.70
Change From Baseline at Week 12-2.5 ± 5.32-6.1 ± 7.25-4.1 ± 4.40
Change From Baseline at Week 14-2.0 ± 7.06-6.4 ± 6.98-0.9 ± 5.49
Change From Baseline at Week 16-3.8 ± 4.44-5.8 ± 6.83-2.3 ± 6.43
Change From Baseline at Week 20—-3.3 ± 7.01-4.7 ± 5.48
Change From Baseline at Week 24—-7.1 ± 7.95-3.8 ± 5.31
Change From Baseline at Week 28—-4.8 ± 10.36-4.0 ± 6.16
Change From Baseline at Week 32—-6.2 ± 7.31-2.4 ± 4.78
Statistical analysis
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.780 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.52 · 95% CI -3.23 to 4.27
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.771 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.50 · 95% CI -2.99 to 3.99
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.984 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.04 · 95% CI -4.22 to 4.14
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.213 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 2.44 · 95% CI -1.47 to 6.35
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.371 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -1.97 · 95% CI -6.40 to 2.45
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.956 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.11 · 95% CI -4.01 to 4.23
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.641 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -1.06 · 95% CI -5.65 to 3.53
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.876 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.33 · 95% CI -4.61 to 3.95
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.458 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -1.86 · 95% CI -6.91 to 3.18
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.769 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -0.68 · 95% CI -5.37 to 4.00
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.699 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -1.14 · 95% CI -7.07 to 4.80
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.687 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 1.10 · 95% CI -4.41 to 6.62
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.944 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.20 · 95% CI -5.55 to 5.95
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.351 (From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 2.48 · 95% CI -2.87 to 7.83
SecondaryChange From Baseline in Anti-acetylcholine Receptor (AChR) Antibody Levels

Clinical laboratory evaluations of anti-AChR antibodies were tested to monitor disease activity. MMRM was used for the analysis.

Time frame:
Baseline up to Week 32
Reported as:
Mean · nmol/L
Change From Baseline in Anti-acetylcholine Receptor (AChR) Antibody Levels
nmol/LTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
Change From Baseline at Week 26.300 ± 25.3514-19.452 ± 50.5551-3.450 ± 5.7767
Change From Baseline at Week 3-3.989 ± 22.9732-14.821 ± 44.47762.509 ± 17.5221
Change From Baseline at Week 40.976 ± 11.7759-24.253 ± 51.262713.680 ± 87.1669
Change From Baseline at Week 5-8.199 ± 13.9571-32.251 ± 58.3701-9.831 ± 26.2188
Change From Baseline at Week 6-19.152 ± 49.2221-27.518 ± 52.6672-2.148 ± 23.2543
Change From Baseline at Week 7-11.235 ± 26.2159-33.261 ± 56.3495-9.882 ± 16.2972
Change From Baseline at Week 87.731 ± 27.8994-39.386 ± 72.3110-5.668 ± 10.4493
Change From Baseline at Week 10-37.473 ± 120.9186-37.083 ± 60.8092-6.654 ± 7.8236
Change From Baseline at Week 12-0.832 ± 31.0318-38.430 ± 64.4594-7.827 ± 11.2120
Change From Baseline at Week 1412.729 ± 49.8823-40.771 ± 74.3624-8.058 ± 15.8407
Change From Baseline at Week 163.501 ± 9.8729-49.843 ± 77.6316-4.909 ± 8.8478
Change From Baseline at Week 20—-52.217 ± 83.1537-4.378 ± 7.7297
Change From Baseline at Week 24—-43.079 ± 77.4438-4.802 ± 10.5639
Change From Baseline at Week 28—-73.786 ± 111.0044-6.044 ± 11.3755
Change From Baseline at Week 32—-51.296 ± 67.3437-5.485 ± 11.8380
Statistical analysis
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.090 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -27.90 · 95% CI -60.18 to 4.38
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.328 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -15.77 · 95% CI -47.50 to 15.96
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.441 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -12.65 · 95% CI -44.94 to 19.63
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.931 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 1.39 · 95% CI -30.33 to 33.12
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.087 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -28.18 · 95% CI -60.46 to 4.11
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.783 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 4.44 · 95% CI -27.29 to 36.16
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.077 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -29.08 · 95% CI -61.36 to 3.21
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.330 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -15.72 · 95% CI -47.45 to 16.00
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.400 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -14.14 · 95% CI -47.19 to 18.91
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =1.000 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: 0.00 · 95% CI -32.18 to 32.19
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.117 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -26.47 · 95% CI -59.64 to 6.69
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.436 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -12.75 · 95% CI -44.94 to 19.44
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.005 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -47.91 · 95% CI -81.54 to -14.29
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.215 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -20.48 · 95% CI -52.92 to 11.95
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.815 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -3.97 · 95% CI -37.34 to 29.40
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.794 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -4.31 · 95% CI -36.84 to 28.22
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.033 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -36.78 · 95% CI -70.48 to -3.08
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.513 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -10.79 · 95% CI -43.26 to 21.67
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.002 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -56.21 · 95% CI -91.69 to -20.73
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.036 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -36.94 · 95% CI -71.39 to -2.48
  • TAK-079 Placebo-matching vs TAK-079 300 mg · MMRM · p = =0.001 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -62.98 · 95% CI -100.64 to -25.31
  • TAK-079 Placebo-matching vs TAK-079 600 mg · MMRM · p = =0.130 (From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.) · Difference in ls mean: -28.81 · 95% CI -66.12 to 8.51
SecondaryChange From Baseline in Anti- Muscle-specific Tyrosine Kinase (MuSK) Titer Levels

Clinical laboratory evaluations of anti-MuSK antibodies were tested to monitor disease activity. Data is reported for participants who were positive for anti-MuSK antibodies at baseline.

Time frame:
Baseline up to Week 32
Reported as:
Mean · titer
Change From Baseline in Anti- Muscle-specific Tyrosine Kinase (MuSK) Titer Levels
titerTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
Change From Baseline at Week 20.0 ± NA-160.0 ± 226.27—
Change From Baseline at Week 30.0 ± NA-200.0 ± 169.71—
Change From Baseline at Week 40.0 ± NA-240.0 ± 339.41—
Change From Baseline at Week 50.0 ± NA-240.0 ± 339.41—
Change From Baseline at Week 60.0 ± NA-240.0 ± 339.41—
Change From Baseline at Week 70.0 ± NA-240.0 ± 339.41—
Change From Baseline at Week 80.0 ± NA-280.0 ± 395.98—
Change From Baseline at Week 100.0 ± NA-280.0 ± 395.98—
Change From Baseline at Week 120.0 ± NA-300.0 ± 424.26—
Change From Baseline at Week 140.0 ± NA-300.0 ± 424.26—
Change From Baseline at Week 160.0 ± NA-300.0 ± 424.26—
Change From Baseline at Week 20—0.0 ± NA—
Change From Baseline at Week 24—-310.0 ± 438.41—
Change From Baseline at Week 28—-310.0 ± 438.41—
Change From Baseline at Week 32—-310.0 ± 438.41—
SecondaryPercentage of Participants With 2-point Reduction in MG-ADL Total Score

The percentage of responders with at least a 2-point reduction in MG-ADL total score from baseline is reported. MG-ADL is a participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. Percentages are rounded off to whole number at the nearest decimal.

Time frame:
At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32
Reported as:
Number · percentage of participants
Percentage of Participants With 2-point Reduction in MG-ADL Total Score
percentage of participantsTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
Week 450.0075.0058.33
Week 691.6775.0058.33
Week 883.3366.6766.67
Week 1083.3383.3350.00
Week 1275.0075.0050.00
Week 1466.6775.0050.00
Week 1666.6766.6733.33
Week 200.066.6758.33
Week 240.058.3358.33
Week 280.058.3358.33
Week 320.041.6741.67
SecondaryPercentage of Participants With 3-point Reduction in QMG Total Score

The percentage of responders with at least a 3-point reduction in QMG total score from baseline is reported. QMG is a physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. Percentages are rounded off to whole number at the nearest decimal.

Time frame:
At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32
Reported as:
Number · percentage of participants
Percentage of Participants With 3-point Reduction in QMG Total Score
percentage of participantsTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
Week 425.0050.0016.67
Week 616.6741.6733.33
Week 833.3366.6733.33
Week 1033.3366.6733.33
Week 1241.6775.0025.00
Week 1433.3366.6725.00
Week 1633.3358.3333.33
Week 200.041.6733.33
Week 240.041.6733.33
Week 280.041.6725.00
Week 320.016.6716.67
SecondaryPercentage of Participants With 3-point Reduction in MGC Total Score

The percentage of responders with at least a 3-point reduction in MGC total score from baseline is reported. MGC is an assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Items are scored based on 4 potential levels of impact: normal, mild, moderate, or severe with a total score of 0 to 50; the higher score indicates worse MG disease activity. Percentages are rounded off to whole number at the nearest decimal.

Time frame:
At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32
Reported as:
Number · percentage of participants
Percentage of Participants With 3-point Reduction in MGC Total Score
percentage of participantsTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
Week 466.6775.0041.67
Week 683.3366.6758.33
Week 883.3383.3358.33
Week 1083.3375.0050.00
Week 1275.0091.6758.33
Week 1466.6783.3350.00
Week 1666.6775.0041.67
Week 200.075.0058.33
Week 240.066.6750.00
Week 280.058.3350.00
Week 320.041.6725.00

Adverse events

Collected over From signing the informed consent form up to end of long-term follow-up (up to Week 32). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAK-079 Placebo-matching0/12 (0%)1/12 (8.3%)8/12 (66.7%)
TAK-079 300 mg0/12 (0%)1/12 (8.3%)9/12 (75%)
TAK-079 600 mg0/12 (0%)1/12 (8.3%)11/12 (91.7%)
Most frequent serious events
Most frequent serious events
EventTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
EnteritisGastrointestinal disorders1/120/120/12
GastroenteritisInfections and infestations1/120/120/12
Myasthenia gravisNervous system disorders0/120/121/12
Suicidal ideationPsychiatric disorders0/121/120/12
Most frequent other events
Showing 10 of 68
Most frequent other events
EventTAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mg
ChillsGeneral disorders0/120/123/12
PyrexiaGeneral disorders1/122/123/12
FatigueGeneral disorders0/121/122/12
NasopharyngitisInfections and infestations1/120/122/12
Abdominal wall abscessInfections and infestations1/120/120/12
Abscess limbInfections and infestations0/120/121/12
Alanine aminotransferase increasedInvestigations0/120/121/12
AnaemiaBlood and lymphatic system disorders0/120/121/12
Angle closure glaucomaEye disorders0/120/121/12
ArthralgiaMusculoskeletal and connective tissue disorders0/120/121/12

Baseline characteristics

Safety Analysis Set included participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)TAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mgTotal
Mean46.5 ± 18.0345.3 ± 12.4756.3 ± 14.4249.4 ± 15.54
Sex: Female, Male
Sex: Female, Male(Participants)TAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mgTotal
Female96722
Male36514
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mgTotal
Hispanic or Latino2013
Not Hispanic or Latino9121132
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mgTotal
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White10121133
More than one race0000
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(Participants)TAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mgTotal
Canada0112
Poland1225
Serbia57517
Spain3014
United States3238
Height
Height(cm)TAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mgTotal
Mean164.67 ± 9.435175.39 ± 8.911171.38 ± 10.910170.48 ± 10.511
Weight
Weight(kg)TAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mgTotal
Mean85.11 ± 25.60786.28 ± 21.13288.38 ± 25.67286.59 ± 23.568
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)TAK-079 Placebo-matchingTAK-079 300 mgTAK-079 600 mgTotal
Mean31.33 ± 8.86727.74 ± 4.85230.22 ± 9.31529.76 ± 7.855

4 further baseline measures are reported on the registry.

08

Study locations

50 sites
  • The University of Arizona Medical Center
    Tucson, Arizona 85713, United States
  • Stanford Neuroscience Health Center
    Palo Alto, California 94304, United States
  • University of California Davis Medical Center
    Sacramento, California 95816, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • George Washington University
    Washington, District of Columbia 20037, United States
  • SFM Clinical Research, LLC
    Boca Raton, Florida 33487, United States
  • Neurology Associates PA
    Maitland, Florida 32751, United States
  • Medsol Clinical Research Center Inc
    Port Charlotte, Florida 33952, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Consultants In Neurology
    Northbrook, Illinois 60062, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Michigan State University
    East Lansing, Michigan 48824, United States
  • Neurology and Sleep Disorders Clinic
    Columbia, Missouri 65212, United States
  • Hospital For Special Surgery
    New York, New York 10021, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Carolinas HealthCare System Neurosciences Institute-Neurology
    Charlotte, North Carolina 28207, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Austin Neuromuscular Center
    Austin, Texas 78756, United States
  • The University of Texas South Western Medical Center
    Dallas, Texas 75390, United States
  • Central Texas Neurology Consultants PA
    Round Rock, Texas 78681, United States
  • Center for Neurological Disorders
    Milwaukee, Wisconsin 53215, United States
  • The Medical College of Wisconsin, Inc.
    Milwaukee, Wisconsin 53226, United States
  • The Governors of the University of Calgary
    Calgary, Alberta T3M 1M4, Canada
  • Vancouver General Hospital (VGH)
    Vancouver, British Columbia V6E2E3, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Fondazione Policlinico Universitario A Gemelli
    Roma, Lazio 00168, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Firenze, 50139, Italy
  • IRCCS AOU San Martino
    Genova, 16132, Italy
  • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta
    Milano, 20133, Italy
  • Azienda Ospedaliera Sant'andrea
    Rome, 00189, Italy
  • Neurocentrum Bydgoszcz sp. z o.o.
    Bydgoszcz, Kujawsko-pomorskie 85-796, Poland
  • Centrum Neurologii Klinicznej Sp. z o.o.
    Krakow, Malopolskie 31-505, Poland
  • Centrum Medyczne NeuroProtect
    Warsaw, 01-684, Poland
  • Centrum Medyczne Warszawa - PRATIA - PPDS
    Warszawa, 01-868, Poland
  • Clinical Center of Serbia - PPDS
    Belgrade, 11000, Serbia
  • Military Medical Academy
    Belgrade, 11000, Serbia
  • Clinical Center Nis
    Nis, 18000, Serbia
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Hospital Universitario Vall d'Hebron - PPDS
    Barcelona, 08035, Spain
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario La Paz - PPDS
    Madrid, 28046, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Jul 2022, 29 months.

Results were first posted in Jun 2023, 10 months after primary completion.

Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2019
First posted
Nov 12, 2019
StartActual
Jan 14, 2020
Primary completionActual
Jul 12, 2022
CompletionActual
Jul 12, 2022
Results first posted
Jun 2, 2023
Last update
Jun 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04159805
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 12, 2019
Start date
Jan 14, 2020
Primary completion
Jul 12, 2022
Completion
Jul 12, 2022
Results posted
Jun 2, 2023
Last update
Jun 2, 2023

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezagitamab

Start the discussion